Post-earnings recap
Reported
Tue, Nov 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in stock price by 4.18%. The lack of revenue figures and guidance may have raised concerns among investors about the company's future performance. Overall, the market reacted negatively, reflecting uncertainty regarding their ongoing projects and financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | N/A | +3.05% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their clinical programs. There was no specific guidance provided for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on its ongoing clinical trials and product development.